Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2016.07.045 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Portal Venous Tumor Thrombosis and Visceral Organ Metastasis without Skeletal Involvement in mCRPC: Adverse Prognostic Indicators on Dual Tracer PET/CT and Clinical Outcome after Lu-PSMA-617 PRLT and Cabazitaxel Therapy.
World J Nucl Med
December 2024
Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, Mumbai, India.
Prostate cancer involving visceral organs are occurrences in the later disease course, usually following regional nodal and skeletal involvement, and are refractory to conventional treatment. A 61-year-old male patient presented with locally advanced disease at presentation, which progressed on androgen deprivation therapy and systemic therapy with involvement of the visceral organs (lungs and liver). Portal venous tumor thrombosis involving the right and main branch was also observed on contrast-enhanced computed tomography (CECT) and magnetic resonance imaging (MRI), which showed intense uptake on Ga-labeled prostate-specific membrane antigen positron emission tomography/computed tomography ( Ga-PSMA-11 PET/CT) and F-fluorodeoxyglucose PET/CT ( F-FDG-PET/CT).
View Article and Find Full Text PDFA novel androgen-independent radiotracer with dual targeting of NTSR1 and PSMA for PET/CT imaging of prostate cancer.
Eur J Med Chem
January 2025
Department of Nuclear Medicine, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, PR China. Electronic address:
A substantial proportion of patients with prostate cancer (PCa) develop treatment resistance or mortality after androgen deprivation therapy (ADT). Current methods for identifying and locating recurrent lesions using prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET) imaging, which relies on androgen levels, often result in diagnostic delays. Therefore, the development of an androgen-independent radiotracer is critical for the early identification of recurrent lesions.
View Article and Find Full Text PDFImpact of definitive radiotherapy on metabolic response measured with Ga-PSMA-PET/CT in patients with intermediate-risk prostate cancer.
Prostate
November 2024
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Purpose: To assess the early metabolic response of the primary tumor using Gallium-68 (Ga)-labeled-prostate-specific membrane antigen positron emission tomography (Ga-PSMA-PET/CT), as well as the relationship between PSMA change in the primary tumor and PSA response after definitive radiotherapy (RT), either alone or in combination with androgen deprivation therapy (ADT) in intermediate risk prostate cancer (IR-PCa) patients.
Methods: The clinical data of 71 IR-PCa patients treated with RT alone (36 patients, 50.7%) or RT and ADT (35 patients, 49.
Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II Study.
Cancers (Basel)
May 2024
Department of Oncology, Radiation Oncology Service, Centre Hospitalier Universitaire Vaudois, 1005 Lausanne, Switzerland.
We investigated spatial patterns between primary and recurrent tumor sites and assessed long-term toxicity after dose escalation stereotactic body radiation therapy (SBRT) to the dominant intra-prostatic nodule (DIN). In 33 patients with intermediate-high-risk prostate cancer (PCa), doses up to 50 Gy were administered to the DIN. Recurrence sites were determined and compared to the original tumor development sites through multiparametric MRI and Ga-labeled prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (Ga-PSMA-PET/CT) images.
View Article and Find Full Text PDFPerformance evaluation of iterative PET reconstruction with resolution recovery incorporating Gallium-68 positron range correction.
Med Phys
September 2024
Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
Background: The distance traveled by the positron before annihilation with an electron, the so-called positron range, negatively effects the positron emission tomography (PET) image quality for radionuclides emitting high-energy positrons such as Gallium-68 (Ga).
Purpose: In this study, the effect of a tissue-independent positron range correction for Gallium-68 (Ga-PRC) was investigated based on phantom measurements. The effect of the Ga-PRC was also explored in four patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!